Skip to main content

Want a detailed portfolio tracker?

UNCY
NASDAQ
$5.45

Unicycive Therapeutics Inc (UNCY)

Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for kidney diseases, particularly in the management of hyperphosphatemia. With its proprietary drug candidates aimed at effectively regulating phosphorus levels crucial for renal health, Unicycive is strategically positioned to address significant unmet medical needs within nephrology. The company's strong commitment to research and development, combined with its collaborative partnerships, enhances its potential for innovation and growth. As Unicycive advances through clinical trials, it represents a compelling investment opportunity for institutional investors targeting transformative solutions in the healthcare sector.
Website: https://unicycive.com
Sector:
Healthcare
Industry:
Biotechnology
68 analysts
Strong Buy
Target: $38.59 (+608.07%)

Market Cap

$127M

Free Cash Flow Yield

-23.33%

Beta (5Y)

0.84

Price Chart

Valuation
Market Cap$127M
Forward P/E3.44
P/S23.75
P/B3.79
Profitability
EBITDA-$30M
EPS-$1.92
Financial Health
Free Cash Flow Yield-23.33%
Growth & Risk
Beta (5Y)0.84
Sharpe Ratio0.58